Cartesian Therapeutics, Inc. — 2022 Q2 SEC Filing Summary
Filing-entity note: The supplied Form 10-Q is filed by Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It covers the quarter and six months ended June 30, 2022 and contains unaudited consolidated financial statements.
Business Context and Reporting Period
Selecta was a clinical-stage biopharmaceutical company developing its ImmTOR and ImmTOR-IL immune-tolerance platforms. Its lead partnered product, SEL-212 for chronic refractory gout, was in Phase 3 development through Sobi. The company had no approved products and generated no product sales; revenue primarily came from collaboration and license arrangements.
Management expected SEL-212 DISSOLVE II enrollment to be completed in the fourth quarter of 2022, with topline data expected in the first quarter of 2023. The SEL-302 gene-therapy trial clinical hold was removed in March 2022.
Financial Metrics
| Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 |
|---|---|---|---|---|
| Collaboration and license revenue | $39.3 million | $19.7 million | $73.3 million | $30.7 million |
| Research and development expense | $19.2 million | $14.5 million | $36.9 million | $27.5 million |
| General and administrative expense | $6.2 million | $4.7 million | $11.8 million | $10.0 million |
| Operating income (loss) | $13.9 million | $0.5 million | $24.6 million | $(6.7) million |
| Net income (loss) | $8.6 million | $4.6 million | $37.4 million | $(20.0) million |
| Net income (loss) per diluted share | $0.06 | $0.00 | $0.17 | $(0.18) |
| Cash flow from operating activities | Not separately reported for the quarter | $(24.1) million | $(18.2) million |
Reported operating margin was approximately 35% for the quarter and 34% for the six-month period; reported net margin was approximately 22% and 51%, respectively. These margins were not representative of a commercial operating model because revenue was primarily collaboration-related and included milestone, license, supply and reimbursement activity.
Balance Sheet, Debt and Liquidity
- Cash and cash equivalents were $138.1 million at June 30, 2022, compared with $114.1 million at December 31, 2021.
- Marketable securities were $4.0 million, and restricted cash was $1.4 million. Total cash, cash equivalents, restricted cash and marketable securities were approximately $143.4 million.
- Accounts receivable increased to $24.0 million, including amounts due from Sobi and Sarepta.
- Total liabilities were $98.5 million, including $25.9 million of loan payable, $34.9 million of deferred revenue and $26.9 million of warrant liabilities.
- The outstanding principal under the 2020 term loan was $25.0 million. Amortization was deferred to April 1, 2023, with principal payments scheduled through 2025.
- Stockholders’ equity increased to $89.6 million from $22.5 million at year-end 2021, primarily reflecting reported net income and equity financing activity.
- Management stated that available cash, cash equivalents, restricted cash and marketable securities were expected to fund current planned operations for at least twelve months and, in the MD&A, into mid-2024. This estimate depended on assumptions and was subject to significant uncertainty.
Material Changes Versus the Prior Comparable Period
- Six-month collaboration and license revenue increased 139% to $73.3 million, driven primarily by Sobi revenue, $10.2 million from Sarepta, $9.2 million recognized upon termination of the Spark agreement and $1.0 million from Takeda.
- Second-quarter revenue doubled to $39.3 million, including $29.2 million from Sobi and $10.1 million from Sarepta.
- Research and development expense increased 34% for the six-month period to $36.9 million, reflecting higher SEL-212, preclinical, personnel, stock-based compensation and license or milestone costs.
- The company reported six-month net income of $37.4 million versus a $20.0 million net loss in the prior-year period. The improvement was materially affected by collaboration revenue and a $13.9 million gain from the revaluation of warrant liabilities.
- Operating cash use increased to $24.1 million from $18.2 million despite reported net income, primarily because of working-capital changes, including a $42.2 million reduction in deferred revenue and a $14.1 million increase in accounts receivable.
- In April 2022, the company raised approximately $36.9 million net from an offering of 27.4 million common shares and warrants to purchase up to 20.6 million additional shares. It also raised $1.7 million through its at-the-market program.
- Shares outstanding increased to 152.7 million at June 30, 2022 from 123.6 million at December 31, 2021, creating material potential dilution. Outstanding warrants totaled 31.2 million, and options, restricted stock units and other reserved shares added further dilution exposure.
Guidance, Outlook, Risks and Unusual Items
- Management expected operating losses to continue over the foreseeable future and stated that additional financing could be required. Future funding could involve equity dilution, debt or the surrender of valuable collaboration rights.
- Revenue was expected to fluctuate significantly based on the timing of collaborator payments, milestones, clinical-supply shipments and reimbursements. There was no clear recurring product-revenue guidance.
- Completion of DISSOLVE II enrollment generated a $10.0 million Sobi milestone and increased the trial target to 153 subjects to replace potentially lost Russia and Ukraine participants. Topline results were expected in the first quarter of 2023.
- COVID-19, supply-chain disruption and the Russia-Ukraine conflict could affect patient participation, clinical execution, manufacturing and drug supply. The filing stated that COVID-19 had not materially affected clinical programs as of the filing date.
- The company recorded a $0.9 million accrued liability related to a stockholder derivative litigation settlement. The settlement was approved by the Delaware Court of Chancery on July 21, 2022.
- Warrant liabilities were remeasured through earnings and were sensitive to the share price, volatility and other Black-Scholes assumptions. The second-quarter revaluation produced a $4.6 million expense, while the six-month revaluation produced a $13.9 million gain.
- Management identified clinical-trial execution, regulatory approval, manufacturing capacity, intellectual property, dependence on collaborators, cybersecurity, key personnel and access to capital as material risks.
Most Important Facts for Investors to Verify
- Confirm that the filing pertains to Selecta Biosciences, Inc. rather than Cartesian Therapeutics, Inc.
- Assess the sustainability and timing of collaboration revenue, particularly Sobi and Sarepta amounts, versus underlying operating cash use.
- Review DISSOLVE I and DISSOLVE II enrollment, topline data timing and the status of the $10.0 million Sobi milestone.
- Reconcile liquidity with the company’s mid-2024 runway estimate, debt amortization beginning in April 2023 and potential need for additional financing.
- Evaluate dilution from the April 2022 financing, 31.2 million outstanding warrants, employee equity awards and other reserved shares.
- Separate recurring operating performance from non-recurring items, including warrant revaluation gains and revenue recognized upon the Spark agreement termination.
- Monitor regulatory, manufacturing, supply-chain, geopolitical, cybersecurity and clinical-trial risks, including the status of SEL-302 and other preclinical programs.